iBio-logo.jpg
iBio Announces Closing of $3.5 Million Underwritten Public Offering
December 09, 2022 16:05 ET | iBio, Inc.
BRYAN, Texas, Dec. 09, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the closing of its...
iBio-logo.jpg
iBio Announces Pricing of $3.5 Million Underwritten Public Offering
December 06, 2022 23:27 ET | iBio, Inc.
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the pricing of its...
iBio-logo.jpg
iBio Announces Proposed Underwritten Public Offering
December 06, 2022 16:01 ET | iBio, Inc.
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced it intends to offer...
iBio-logo.jpg
iBio to Participate in the JMP Securities Hematology and Oncology Summit
December 06, 2022 08:00 ET | iBio, Inc.
BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that its Chief...
iBio-logo.jpg
iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022
December 05, 2022 08:00 ET | iBio, Inc.
BRYAN, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today it will present two...
iBio-logo.jpg
iBio Announces CEO Departure
December 02, 2022 16:30 ET | iBio, Inc.
BRYAN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the Board of...
iBio-logo.jpg
iBio Accelerates Transformation to AI-Powered Biotech
November 03, 2022 08:00 ET | iBio, Inc.
– Divesting CDMO business and cGMP biologics manufacturing facility – – Investing in pipeline of immuno-oncology assets and AI-based drug discovery platform – – Restructuring measures to result in...
iBio-logo.jpg
iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update
September 27, 2022 16:10 ET | iBio, Inc.
BRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the...
iBio-logo.jpg
iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline
September 21, 2022 08:30 ET | iBio, Inc.
– Positions Company for leadership in AI-powered drug discovery – – Expands iBio’s immuno-oncology pipeline with three new candidates – – Hosting investor call on September 27th to discuss...
iBio-logo.jpg
iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate
August 16, 2022 09:00 ET | iBio, Inc.
- Manufactured first batch of drug substance under cGMP conditions - - Analysis of challenge study data underway - BRYAN, Texas, Aug. 16, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio”...